News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase III (World)
FDA Slaps Clinical Hold on Alcobra (ADHD)'s Late Stage ADHD Study 9/29/2016
Moberg Pharma AB (Formerly known as Moberg Derma) Begins Patient Enrollment In North America And Europe In Two Phase 3 Studies Of MOB-015 In Onychomycosis 9/28/2016
Galapagos (GLPG.BR) Release: Successful Completion Of Regulatory Consultations To Progress Filgotinib To Phase 3 In Inflammatory Bowel Disease 9/28/2016
Jazz Pharma (JAZZ) Announces That Patient Enrollment Is Complete For The Phase 3 Studies Of JZP-110 Evaluating Excessive Sleepiness In Obstructive Sleep Apnea 9/27/2016
GW Pharma (GWPH)'s Cannabis-Derived Drug Successful in Third Late-Stage Epilepsy Study 9/26/2016
This Biotech Has the Upper Hand Over Allergan (AGN) and Gilead (GILD) in the Heated Nash Battle 9/23/2016
Armed With Fresh Phase III Data, Novartis AG (NVS) Eyes First-Line Use for Lung Cancer Drug Zykadia 9/23/2016
H. Lundbeck A/S (LUN.CO)'s Phase III Data Crushes Hope for Alzheimer’s Once Again 9/23/2016
Teva (TEVA) Announces Positive Top-Line Data From Second Phase III Study Of SD-809 In Tardive Dyskinesia (TD) 9/22/2016
The Drugmaker That Could Knock Gilead (GILD) Off Its HIV Throne 9/20/2016
Amgen (AMGN), UCB Group (UCBJF.PK)'s Romosozumab Showed Significant Results in Phase III Study 9/19/2016
FDA Takes Back Special Protocol Assessment for Active Biotech (BTPC)'s Laquinimod 9/19/2016
Novo Nordisk A/S (NVO)'s New Diabetes Med Semaglutide Slashes Heart Disease Risk 9/16/2016
Treatment Effects Maintained Over Six Years In Patients With Relapsing Remitting Multiple Sclerosis Who Received Sanofi Genzyme (SNY)’s Lemtrada (Alemtuzumab) In Clinical Trials 9/16/2016
GlaxoSmithKline (GSK)'s Experimental Shingles Vaccine 90% Effective in People Over Age 70 9/15/2016
Innovent Biologics Starts China Trials of Two Biologic Drug Candidates 9/15/2016
GenSight Biologics Receives Approval To Include Teenage Patients In RESCUE And REVERSE Phase III Trials With GS010 In Leber’s Hereditary Optic Neuropathy 9/8/2016
Boehringer Ingelheim Release: New Analysis Showed Dose Adjustment Of Giotrif (Afatinib) Improved Tolerability Without An Apparent Impact On Efficacy In Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer 9/8/2016
Theravance Biopharma (TBPH) Touts Significant Data from Pivotal Phase III FULFIL Study 9/8/2016
Takeda (TKPYY) Initiates Global Phase III Clinical Trial (TIDES) Of Dengue Vaccine Candidate (TAK-003) 9/7/2016
AstraZeneca PLC (AZN)'s Asthma Candidate Does Well in Final Late-Stage Test 9/6/2016
vasopharm BIOTECH GmbH Announces Enrollment Of First Patient In Phase III Traumatic Brain Injury (TBI) Trial 9/6/2016
Faron Pharmaceuticals Ltd. Release: Interim Results 2016: Progress Continued In Traumakine Phase III And With Clevegen Indications Extended 9/6/2016
Boehringer Ingelheim Release: New Data: Spiolto Respimat Significantly Improves Exercise Capacity In People With COPD 9/6/2016
GlaxoSmithKline (GSK) Presents Positive Results From Phase III Fulfil Study Of Closed Triple Combination Therapy Ff/Umec/Vi Versus Symbicort Turbohaler In COPD At ERS International Congress 9/6/2016
Boehringer Ingelheim Release: Tiotropium Respimat Improved Lung Function In Children With Asthma Aged 6-17 And Is Well-Tolerated Compared To Placebo In Children Aged 1-171-5 9/6/2016
MorphoSys AG Initiates Phase 2/3 Trial Of CD19 Antibody MOR208 Plus Bendamustine In Patients With Relapsed Or Refractory DLBCL 9/6/2016
Vectura (VEC.L)'s Asthma Med Flutiform Flunks Final Late-Stage Study 8/30/2016
Adocia's Foot Ulcer Med Flunks Phase III Test 8/26/2016
NeuroDerm (NDRM) Initiates Patient Enrollment In A Phase III Trial Of ND0612L For The Treatment Of Parkinson’s Disease 8/25/2016
Galapagos (GLPG.BR) Release: Finch Filgotinib Phase 3 Program Initiated In Rheumatoid Arthritis 8/23/2016
Mezzion (140410.KQ) And NHLBI Initiate Enrollment In A Pivotal Phase 3 Clinical Trial Of Udenafil In Adolescents With Fontan Surgical Palliation - An Orphan Drug Indication 8/22/2016
Auris Med (EARS)'s Tinnitus Drug Misses Main Goals in Study; Shares Sink 8/18/2016
Indivior Shows Off Late-Stage Opiod Addiction Trial Data 8/17/2016
Vertex (VRTX) Dumps Phase III Cystic Fibrosis Study 8/17/2016
Ascendis Pharma A/S Announces R&D Update To Review Expanded Pipeline And Long-Term Strategic Outlook 8/16/2016
ViiV Healthcare Launches Phase III Programme Evaluating A Two-Drug Regimen Combining Dolutegravir And Lamivudine For HIV-1 Treatment 8/16/2016
Axovant (AXON) Announces Expansion Of Dementia Pipeline And Reports Financial Results For The First Fiscal Quarter Ended June 30, 2016 8/16/2016
OncoGenex (OGXI) Hires Advisor, Seeks Strategic Alternatives After Cancer Drug Custirsen Study Fails 8/16/2016
Acacia Pharma Announces Positive Results From A Pivotal Phase 3 Trial Of BAREMSIS For The Treatment Of Post-Operative Nausea & Vomiting 8/12/2016
Resverlogix (RVX.TO) Announces Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study Of Apabetalone (RVX-208) 8/11/2016
Ascendis Pharma A/S Initiates Phase 3 Registration Trial For TransCon Growth Hormone In Children With Growth Hormone Deficiency 8/11/2016
PharmaMar Announces The IDMC´s Response On The CORAIL Trial Using PM1183 8/11/2016
Eisai Company (ESALY.PK) Release: U.S. FDA Confirms Sufficient Data To Advance Investigational Bace Inhibitor E2609 For Treatment Of Early Alzheimer’s Disease To PHASE III 8/10/2016
ThromboGenics NV (TBGNF) 2-Year OASIS Study Results Published In Ophthalmology, Journal Of The American Academy Of Ophthalmology (AAO) 8/8/2016
Allergan (AGN), Gedeon Richter (RIG2.F) Face Setback in Cariprazine Antidepressant Trial 8/5/2016
Amarin (AMRN) And FDA Reaffirm Concurrence On REDUCE-IT Through Special Protocol Assessment Agreement Amendment 8/4/2016
FDA Bestows Novartis AG (NVS)'s Breast Cancer Pill With Breakthrough Tag 8/3/2016
Sanofi (SNY) And Regeneron (REGN) Announce EMA Acceptance For Review Of Marketing Authorisation Application For Sarilumab 8/1/2016
Eisai Company (ESALY.PK) Presents Results Of Additional Analysis Of Phase III Study Of Anticancer Agent Halaven At 14th JSMO Annual Meeting Plenary Session 8/1/2016
Takeda (TKPYY), Seattle Genetics (SGEN) Show Off Significant Phase III ALCANZA Data for T-Cell Lymphoma 8/1/2016
First Patient Enrolled In Mallinckrodt (MNK) Phase 3 Terlipressin Trial 7/29/2016
AstraZeneca PLC (AZN) Kills Six Pipeline Programs 7/28/2016
TauRx Pharma's Much-Watched Alzheimer's Drug Flops in Trial 7/27/2016
Boehringer Ingelheim Halts Two Phase III Trials for Lung Cancer Drug Gilotrif 7/27/2016
Astellas (ALPMY) And FibroGen (FGEN) Announce First Patient Treated In Phase III Studies And Positive Phase II Results Of Roxadustat In Patients With Chronic Kidney Disease In Japan 7/26/2016
Shire (SHPG) Release: ONIVYDE Receives Positive CHMP Opinion For Treatment Of Patients With Metastatic Adenocarcinoma Of The Pancreas Who Have Progressed Following Gemcitabine Based Therapy 7/25/2016
Alcobra (ADHD) Granted European Orphan Drug Designation For Metadoxine In Fragile X Syndrome 7/19/2016
ViiV Healthcare Release: ARIA Study Shows Superior Efficacy Of Triumeq For Treatment-Naïve Women Living With HIV 7/18/2016
Biogen (BIIB) And Sobi To Showcase Long-Term Efficacy And Safety Data From Extended Half-Life Hemophilia Therapies At World Federation Of Hemophilia 2016 World Congress 7/18/2016
Alizé Pharma To Present Results From AZP-531 Phase II Trial In Prader-Willi Syndrome At Two Upcoming Scientific Conferences 7/18/2016
Nuvo Pharmaceuticals Inc. Announces Pennsaid 2% Phase 3 Trial To Support Regulatory Approvals In The E.U., Canada And Australia 7/13/2016
Cipher Pharma (DND.TO) Announces Ozenoxacin Accepted For Review By Health Canada 7/12/2016
Novo Nordisk A/S (NVO) To Present 28 Abstracts At The World Federation Of Hemophilia World Congress In Orlando 7/12/2016
ENGOT And Tesaro (TSRO) Partnership Generates Positive Data From ENGOT-OV16/NOVA Phase 3 Trial 7/11/2016
Bausch & Lomb And Nicox Announce The Publication Of Latanoprostene Bunod Ophthalmic Solution 0.024% Phase 3 Study Results In American Journal Of Ophthalmology 7/6/2016
Merck KGaA (MKGAF.PK), Darmstadt, Germany, And Pfizer (PFE) Initiate Phase III Trial To Evaluate Avelumab As First-Line Treatment For Ovarian Cancer 7/6/2016
Merck & Co. (MRK) And Pfizer (PFE) Initiate Phase III Trial To Evaluate Avelumab As First-Line Treatment For Ovarian Cancer 7/6/2016
Teva (TEVA) And The Huntington Study Group Announce Publication Of Pivotal Phase III Data On Deutetrabenazine (SD-809) In Huntington Disease From First-HD Trial In JAMA 7/5/2016
Allergan (AGN) Receives Positive Opinion Through European Decentralised Procedure For BELKYRA (Deoxycholic Acid) For Patients With Submental Fullness 7/1/2016
Mesoblast (MSB.AX) Plans to Reduce FY17 Cash Burn to Fund Clinical Operations and Phase III Heart Failure Trial 7/1/2016
BeyondSpring Pharmaceuticals's Global Phase III Non-Small Cell Lung Cancer Clinical Trial For Plinabulin Launches In China 6/28/2016
Celyad’s CHART-1 Phase III Shows No Significant Difference on Primary Endpoint 6/28/2016
Phase III Data Show Bayer (BAY)'s Stivarga (Regorafenib) Improved Overall Survival In Previously Treated Patients With Unresectable Liver Cancer 6/28/2016
GW Pharma (GWPH)’s Epidiolex Meets Primary Endpoint in Phase III 6/27/2016
AnGes Terminates Phase III HGF Plasmid, Starts New Plan 6/27/2016
Roche (RHHBY) CEO 'Sleeping Much Better' Following Positive News About Three New Drugs 6/23/2016
Innocoll (INNL) Announces The Completion Of Enrollment In Two Pivotal Phase III Clinical Trials Of COGENZIA For The Treatment Of Diabetic Foot Infections 6/23/2016
Concordia Healthcare Announces PDT With Photofrin Data And Provides Corporate Update 6/20/2016
GlaxoSmithKline (GSK)'s Lung Drug Passes Phase III Test 6/20/2016
Circassia (CIR.L) Stock Crashes as Allergy Drug Flunks Crucial Phase III Study 6/20/2016
Can-Fite BioPharma (CFBI) Reports New Data Showing Its Psoriasis Drug May Offer Efficacy Similar To Industry Leading Biologics Without Harmful Side Effects 6/16/2016
IBSA Release: Prescription Chondroitin Sulphate Is As Efficacious As Celecoxib And Better Than Placebo In Knee Osteoarthritis 6/14/2016
Novo Nordisk Canada Inc. (NVO) Release: Faster-Acting Insulin Aspart Showed A Statistically Significant Reduction In Hba(1c) In Type 1 Diabetes And A Comparable HbA(1c) Reduction In Type 2 Diabetes Versus NovoRapid (Insulin Aspart) 6/14/2016
Sanofi (SNY)'s New Diabetes Combo Nails Late-Stage Goals 6/13/2016
REPEAT/Janssen-Cilag International NV (JNJ)’s EPREX (Epoetin Alfa) Demonstrates Effectiveness As A Treatment For Anaemia In Patients With Low Or Intermediate-1 Risk Myelodysplastic Syndromes 6/13/2016
Janssen-Cilag International NV (JNJ)’s EPREX (Epoetin Alfa) Demonstrates Effectiveness As A Treatment For Anaemia In Patients With Low Or Intermediate-1 Risk Myelodysplastic Syndromes 6/13/2016
Janssen-Cilag International NV (JNJ) Release: Daratumumab Significantly Extended Progression-Free Survival In Combination With Lenalidomide And Dexamethasone In Patients With Multiple Myeloma 6/10/2016
Bristol-Myers Squibb Canada (BMY) Release: Canada's Health Technology Assessment Agency Gives Positive Recommendation For OPDIVO To Treat Non-Small Cell Lung Cancer 6/9/2016
GlaxoSmithKline (GSK), Johnson & Johnson (JNJ)'s Rheumatoid Arthritis Drug Meets Goals in Large Late-Stage Study 6/8/2016
New Janssen R&D Phase 3 Data In Patients With Moderately To Severely Active Rheumatoid Arthritis Shows Sirukumab Significantly Inhibited Radiographic Progression And Improved Signs And Symptoms Of Disease 6/8/2016
Samsung Bioepis Announces New Data On Three Anti-TNF--a Biosimilar Molecules At The Annual European Congress On Rheumatology (EULAR 2016) 6/8/2016
Can-Fite BioPharma (CFBI) Submits Psoriasis Phase III Protocol And Registration Plan To European Medicines Agency For Piclidenoson (CF101) 6/7/2016
ASCO2016: Mylan (MYL)-BioCon (BIOCON.NS)'s Biosimilar Cancer Drug Comparable to Roche (RHHBY)'s Herceptin 6/6/2016
ASCO2016: SELLAS Life Sciences Group Announces Exciting Results For Galinpepimut-S, The Company's WT1 Vaccine, In Patients With Acute Myeloid Leukemia (AML) And Malignant Pleural Mesothelioma (MPM), As Presented At The 2016 ASCO Annual Meeting 6/6/2016
Merck & Co. (MRK) Partners With Array BioPharma (ARRY) And Pierre Fabre To Initiate BRAF-Mutant CRC Phase III Trial 6/6/2016
ASCO2016: OBI Pharma (SHPG) Presents Data For Novel Investigational OBI-822/OBI-821 In Patients With Metastatic Breast Cancer At The 2016 American Society Of Clinical Oncology Annual Meeting 6/6/2016
ASCO2016: Janssen Pharmaceutical Release: Daratumumab (DARZALEX) Combination Therapy Significantly Extended Progression-Free Survival In Previously Treated Patients With Multiple Myeloma 6/6/2016
Theravance Biopharma (TBPH) Completes Enrollment In All Three Phase 3 Clinical Studies Of Revefenacin (TD-4208) For Treatment Of Chronic Obstructive Pulmonary Disease (COPD) 6/2/2016
Astellas (ALPMY) And Medivation (MDVN) Initiate Phase III Trial Of Enzalutamide In Patients With Triple-Negative Breast Cancer 6/2/2016
Boehringer Ingelheim Launches Ambitious ELUXA Trial Programme To Broadly Investigate Promising Lung Cancer Compound Olmutinib 6/2/2016
Nektar Therapeutics (NKTR), DAIICHI SANKYO EUROPE GmbH Strike $80 Million+ ONZEALD Pact 6/1/2016
Can-Fite BioPharma (CFBI) Reaches Agreement With European Medicines Agency On Pivotal Phase III Clinical Trial With Piclidenoson (CF101) In Rheumatoid Arthritis 6/1/2016
PharmaEngine, Inc. Announces Initiation Of Global Pivotal Trial Of PEP503 (NBTXR3) In Soft Tissue Sarcoma In Asia Pacific Region 6/1/2016
Helsinn Group To Present At ASCO Pooled Follow Up Efficacy Data Analysis From Two Phase III Studies For Anamorelin In Cachectic Patients With Non-Small Cell Lung Cancer (NSCLC) 6/1/2016
Daiichi Sankyo, Inc. (DSNKY) Not Proceed With Lung Cancer Study 5/31/2016
Novartis AG (NVS) Trial Stopped Early on Positive Data, Gets Ready to Take on Pfizer (PFE)'s Ibrance 5/31/2016
Innocoll (INNL)'s Painkiller Passes Final Phase III Tests, Heads for 2017 Launch 5/25/2016
SELLAS Life Sciences Group Announces Upcoming Presentation Of Phase 2 Clinical Results For WT1 Cancer Vaccine At The 2016 ASCO Annual Meeting 5/24/2016
Shionogi Release: Two Naldemedine Phase III Studies Show Consistent Improvement Of Opioid-Induced Constipation 5/24/2016
Alkermes (ALKS) To Present Data On ALKS 5461 At Upcoming American Society Of Clinical Psychopharmacology Annual Meeting 5/24/2016
Norgine Release: New Positive Phase III Study For NER1006 - The First 1 Litre PEG-Based Bowel Preparation 5/24/2016
After Initial Miss, GlaxoSmithKline (GSK)'s Pioneering Lung Study Shows Positive Results 5/24/2016
FDA Questions Study Findings, Practicality of Novo Nordisk A/S (NVO)'s Diabetes Drug Ideglira 5/23/2016
Genmab A/S (GEN.CO) Announces Positive Topline Result In Phase III POLLUX Study Of Daratumumab In Relapsed Or Refractory Multiple Myeloma 5/19/2016
AstraZeneca PLC (AZN)'s Gastric Cancer Drug Lynparza Flunks Phase III Test 5/18/2016
AstraZeneca PLC (AZN)'s Asthma Drug Hits Phase III Goal, Predicted to Reach Market in 2017 5/18/2016
European Scleroderma Trial Investigating Cytori Therapeutics (CYTX) Cell Therapy To Be Presented In Japan 5/17/2016
SillaJen Announces Commercial Manufacturing Agreement With ABL Europe For Lead Oncolytic Virus, Pexa-Vec 5/16/2016
Theravance Biopharma (TBPH) Release: New Data Analyses From Phase 3 ATTAIN Trials Support VIBATIV (Telavancin) As A Treatment For Staphylococcus Aureus HABP/VABP, Including Cases Caused By MRSA 5/16/2016
OncoGenex (OGXI) Reports Financial Results For First Quarter 2016 5/13/2016
Hutchison China MediTech (Chi-Med) Completes Enrollment Of 416 Patients In Pivotal Phase III FRESCO Trial With Fruquintinib in Colorectal Cancer 5/13/2016
Theravance Biopharma (TBPH) To Present New Data Analyses From Phase 3 ATTAIN Trials Of VIBATIV (Telavancin) In Treatment Of HABP/VABP At American Thoracic Society 2016 International Conference 5/12/2016
Santen Europe Release: Vekacia (Ciclosporin 1mg/mL Eye Drops) Pivotal Trial Meets Primary And Key Secondary Endpoints 5/11/2016
Allergan (AGN) And Gedeon Richter (RIG2.F) Announce Positive Phase III Results For Ulipristal Acetate 5 And 10 Mg In The Treatment Of Uterine Fibroids 5/9/2016
DelMar Pharma Announces $5.6 Million Private Placement Of Preferred Shares 5/5/2016
ProMetic Life Sci (PFSCF.PK) Announces Successful Treatment Of A Plasminogen-Deficient Patient Under An Expanded Access (Compassionate Use) Protocol In The USA 5/3/2016
Intec Pharma Ltd. Appoints VP Of Clinical And Regulatory Affairs 5/3/2016
Can-Fite BioPharma (CFBI) To Present Data On Cf602 In The Treatment Of Erectile Dysfunction At American Urological Association's Annual Meeting 5/2/2016
Elekta Release: New Data Presented At ESTRO 35 Show Positive Cosmesis And Favorable Late Side Effects After Accelerated Partial Breast Irradiation (APBI) With Multicatheter Interstitial Brachytherapy 5/2/2016
Can-Fite BioPharma (CFBI) To Present At Joseph Gunnar & Co.'s Pioneers 2016 Conference In New York City On May 5, 2016 4/29/2016
Novartis AG (NVS) Granted Three Breakthrough Badges for Ilaris 4/27/2016
DalCor Randomizes First Patient In The DalGenE Phase 3 Cardiovascular Outcomes Trial 4/26/2016
JAMA Publishes Phase III Data From Allergic Asthma Trial With ALK-Abello A/S's House Dust Mite SLIT-Tablet, ACARIZAX 4/26/2016
PHARNEXT Announces The Opening Of The First U.S. Study Site For Its PLEO-CMT International Pivotal Phase 3 Trial In Charcot-Marie-Tooth Disease Type 1A 4/25/2016
Merck KGaA (MKGAF.PK) Release: Phase III TAILOR Landmark Study Demonstrates Significant Benefits of Erbitux in Combination with FOLFOX Over FOLFOX Alone 4/25/2016
Genmab A/S (GEN.CO) Announces Daratumumab Data To Be Presented At 2016 ASCO Annual Meeting 4/20/2016
Basilea (BSLN.SW) Wins $100 Million Contract to Fund Phase III Ceftobiprole Program 4/20/2016
Teva (TEVA) Presents New Data For SD-809 In Huntington Disease At 68th American Academy of Neurology Annual Meeting In Vancouver, B.C. 4/18/2016
AbbVie (ABBV) Announces Real-World Data With VIEKIRAX (Ombitasvir/Paritaprevir/Ritonavir Tablets) And EXVIERA (Dasabuvir Tablets) From Large German Hepatitis C-Registry 4/15/2016
Medivir (MVRBF): New Data For Simeprevir Will Be Presented At Easl's International Liver Congress 2016 4/11/2016
Addex Therapeutics (ADXN.SW) Reports Positive Results Of An mGlu5 Receptor Occupancy Study With Dipraglurant In Healthy Volunteers 4/11/2016
Bay Area's Tobira Strikes a $74.5 Million Evogliptin and Cenicriviroc Deal with Dong-A ST 4/11/2016
CHMP Issues Positive Opinion To Include New Data In European Label For XTANDI (enzalutamide) 4/7/2016
Axovant (AXON) To Present At The Goldman, Sachs & Co. Alzheimer's Symposium 4/5/2016
SELLAS Life Sciences Group Receives A Favorable Opinion For European Orphan Drug Designations For WT1 Cancer Vaccine (galinpepimut-S) For The Treatment Of Acute Myeloid Leukemia And For Malignant Pleural Mesothelioma 4/5/2016
Merck & Co. (MRK) And Pfizer (PFE) Announce First Patient Treated In Phase III Combination Study With Avelumab And INLYTA In Renal Cell Carcinoma 4/5/2016
Braeburn Pharma And Camurus Announce Enrollment Goals Reached In Two Pivotal Phase 3 Trials Of CAM2038 For Treatment Of Opioid Dependence 4/5/2016
Amgen (AMGN), UCB Group (UCBJF.PK)'s Romosozumab Tops Teriparatide in Phase III Osteoporosis Study 4/4/2016
Can-Fite BioPharma (CFBI) To Participate In BIO-Europe Partnering Conference On April 4-6, 2016 In Stockholm, Sweden 4/4/2016
Chugai Pharma Europe Announces Positive Phase III Results Of Aplidin 4/4/2016
Onxeo Announces Positive DSMB Recommendation To Continue Livatag Relive Study In HCC 4/4/2016
Taiho Pharma's TAS-102 Meets Primary Endpoint Of Improving Overall Survival In Phase III TERRA Study In Asian Patients With Refractory Metastatic Colorectal Cancer 4/1/2016
Specialised Therapeutics Asia Release: Novel Multiple Myeloma Drug Aplidin Shows Positive Results In Pivotal Phase 3 Study 3/31/2016
Auris Medical AG (EARS) Completes Enrollment Of TACTT2 Phase 3 Trial Of AM-101 In Acute Inner Ear Tinnitus 3/30/2016
Mezzion (140410.KQ) Receives Special Protocol Assessment (SPA) Agreement From FDA For Udenafil Phase 3 Studies In Adolescents With Single Ventricle Congenital Heart Disease With Fontan Physiology 3/24/2016
Medivation (MDVN) Release: Pivotal Phase III Trial Of Enzalutamide Initiated In Metastatic Hormone Sensitive Prostate Cancer 3/24/2016
Advanced Accelerator Applications Provides Lutathera Update 3/23/2016
Mologen AG (MOLGF.PK): All Key Milestones Achieved In 2015 3/22/2016
Acacia Pharma Initiates Second Pivotal Phase 3 Treatment Study With Baremsis (APD421) In Post-Operative Nausea & Vomiting (PONV) 3/21/2016
Amgen (AMGN), UCB Group (UCBJF.PK)'s Romosozumab Shines in Phase III Osteoporosis Trial 3/21/2016
TauRx Pharma Co-Founder's 30-Year Alzheimer's Quest May Bear Fruit in July 3/21/2016
Janssen Research & Development Release: STELARA Induced Clinical Response And Remission In Phase 3 Study For The Treatment Of Patients With Moderate To Severe Crohn's Disease Who Had Previously Failed Or Were Intolerant To Anti-TNF-Alpha Therapy 3/18/2016
Heart Metabolics Limited Announces Multiple Senior Appointments To Management Team 3/15/2016
GW Pharma (GWPH) Shares Double as Cannabis Drug Meets Goals in Phase III Study 3/15/2016
Regeneron (REGN), Sanofi (SNY)'s RA Drug Beats AbbVie (ABBV)'s Blockbuster Humira in Phase III Study 3/14/2016
PTC Therapeutics (PTCT) Provides Update On Health Canada Review Of Translarna (ataluren) For The Treatment Of Duchenne Muscular Dystrophy 3/14/2016
OncoGenex (OGXI) Reports Financial Results for Year End 2015 3/10/2016
TRANSGENE (ENX:TNG) Reports 2015 Financial Results And Provides Outlook For 2016 3/8/2016
Novo Nordisk A/S (NVO) Release: Victoza Significantly Reduced The Risk Of Major Adverse Cardiovascular Events In The LEADER Trial 3/7/2016
Celsion (CLSN) Announces Launch Of The OPTIMA Study In China 3/7/2016
Biofrontera AG Announces Full Results Of Phase III Clinical Trial Evaluating BF-200 ALA For Treatment Of Basal Cell Carcinoma (BCC) 3/7/2016
Green Cross Biotherapeutics Receives Health Canada Approval For Phase III Clinical Trials Of IVIG 10% 3/7/2016
Newron Pharmaceuticals (NWRN) Reports 2015 Financial Results 3/1/2016
AbbVie (ABBV) Receives European Medicines Agency Orphan Drug Designation For Investigational Compound Venetoclax For The Treatment Of Acute Myeloid Leukemia (AML) 2/26/2016
Eli Lilly (LLY) Receives Positive CHMP Opinion For Ixekizumab For The Treatment Of Moderate-To-Severe Plaque Psoriasis 2/26/2016
AbbVie (ABBV) Receives CHMP Positive Opinion For VIEKIRAX (Ombitasvir/Paritaprevir/Ritonavir Tablets) + EXVIERA (Dasabuvir Tablets) Without Ribavirin For The Treatment Of Chronic Hepatitis C In Genotype 1b Patients With Compensated Cirrhosis (Child-Pugh A) In Europe 2/26/2016
Orphan Drug Designation Status for Acerta Pharma Drug Vindicates AstraZeneca PLC (AZN)’s $4 Billion Deal 2/26/2016
PolyPid Ltd. Announces Completion Of $22 Million Series D Financing 2/24/2016
Helsinn Announces Publication Of Anamorelin ROMANA 1 And ROMANA 2 Phase III Studies In The Lancet 2/23/2016
Sirtex Medical (SRX.AX) Release: SIRFLOX Study Published In Journal Of Clinical Oncology 2/23/2016
Novartis AG (NVS)'s Leukemia Drug Gets Breakthrough Designation, Same Week as AstraZeneca PLC (AZN) and Roche (RHHBY) Drugs 2/22/2016
OBI Pharma (SHPG) Reports Topline Results From OBI-822/821 Randomized Controlled Phase 2/3 Clinical Trial In Patients With Metastatic Breast Cancer 2/22/2016
OSE Pharma: First Patients Enrolled And Dosed In The Pivotal Trial Of Phase III Of The Immunotherapy Tedopi For Advanced Non-Small Cell Lung Cancer 2/22/2016
Jazz Pharma (JAZZ) To Present Data From Ongoing Evaluations Of Defibrotide At The 2016 BMT Tandem Meeting 2/18/2016
Roche (RHHBY)'s Multiple Sclerosis Drug Gets Breakthrough Status, Likely to Haunt Biogen (BIIB) 2/18/2016
Biofrontera AG: Pivotal Phase III Data Demonstrate Significant Efficacy And Excellent Safety For BF-200 ALA Treatment Of Superficial Skin Cancer 2/11/2016
Chugai Pharma's Alecensa Trial Stopped Early After Successfully Meeting Primary Endpoint 2/11/2016
Transition Therapeutics (TTH.TO) Announces Second Quarter Fiscal 2016 Financial Results 2/10/2016
Alkermes (ALKS) Announces Initiation Of Second Phase 3 Study Of ALKS 3831 For Schizophrenia 2/10/2016
PharmaMar S.A. Release: The Phase III Clinical Trial Using PM1183 In Treating Ovarian Cancer (CORAIL) Continues Following The IDMC's Positive Recommendation 2/8/2016
Can-Fite BioPharma (CFBI) To Present At BIO CEO & Investor Conference In New York City On February 8, 2016 2/5/2016
Ascendis Pharma A/S To Present At The Leerink Partners Global Healthcare Conference 2/4/2016
ERYtech Pharma To Present At Upcoming Investor Conferences 2/4/2016
OSE Pharma Announces U.S. Initiation Of Atalante 1, The Company’s Global, Pivotal Phase III Trial For Tedopi Immunotherapy In Non-Small Cell Lung Cancer 2/4/2016
Steba Biotech Announces Positive Top-Line Results From Its Latin American Phase 3 Clinical Trial Of TOOKAD In Patients With Localized Prostate Cancer And Obtains First Marketing Authorization In Mexico 2/1/2016
Allergan (AGN)'s Rapastinel Snags Breakthrough Tag from the FDA for Depression 1/29/2016
Valeant (VRX) Announces FDA Acceptance Of BLA Submission For Brodalumab In Moderate-To-Severe Plaque Psoriasis 1/25/2016
Can-Fite BioPharma (CFBI) CEO Dr. Pnina Fishman To Chair Scientific Session At The 2016 Purinergic Signaling And Cancer Immunotherapy Conference In Vancouver On January 26, 2016 1/25/2016
Steba Biotech Completes Its European Phase 3 Clinical Trial Of TOOKAD In Patients With Low-Risk Prostate Cancer And Submits Marketing Authorization Application To The European Medicines Agency 1/25/2016



//-->